Research programme: psychiatric disorder therapeutics - PsyBrain/X-Chem
Latest Information Update: 28 Jul 2018
Price :
$50 *
At a glance
- Originator X-Chem
- Developer PsyBrain; X-Chem
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psychiatric disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Psychiatric-disorders in USA
- 10 Jan 2014 Early research in Psychiatric disorders in USA (unspecified route)